Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 33 of 34.
Jun 2008
18 Jun · Business
Press release dated June 18, 2008, titled "Aurobindo records consolidated Total Income of Rs 2530 crores and Net Profit of Rs.238 crores. Formulation business constitutes 39.4% of the net sales". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jun · Results
Standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 63240 lacs for quarter ending on 31-MAR-2008 against Rs. 53276 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 7608 lacs for the quarter ending on 31-MAR-2008 against Rs. 7811 lacs for the quarter ending on 31-MAR-2007.18 Jun · Dividend
Board of Directors at its meeting held on June 18, 2008 has recommended dividend of 65% (Rs. 3.25 per share of Rs. 5/- each) on its equity share capital of the Company for the year 2007-08 subject to approval of members at the ensuing Annual General Meeting.18 Jun · Results
Standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 223473 lacs for year ending on 31-MAR-2008 against Rs. 197972 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 29078 lacs for the year ending on 31-MAR-2008 against Rs. 22908 lacs for the year ending on 31-MAR-2007.18 Jun · Results
Consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 243590 lacs for year ending on 31-MAR-2008 against Rs. 225022 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 23848 lacs for the year ending on 31-MAR-2008 against Rs. 20096 lacs for the year ending on 31-MAR-2007.10 Jun · Business
Press release dated June 10, 2008, titled "Aurobindo Pharma receives final approval for Zaleplon Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jun · Board meeting
To consider among other business, the Audited Financial Results of the Company for the Year ended March 31, 2008 and also to recommend Dividend, if any for the year ended March 31, 2008.
May 2008
27 May · Business
Press release dated May 27, 2008, titled "Aurobindo Pharma receives final approval for Benazepril Hydrochloride tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 May · Business
Press release dated May 12, 2008, titled "Aurobindo Pharma receives nine product approvals from MCC- South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 May · Results
Aurobindo Pharma Ltd had informed the Exchange regarding the proposal to pass a Special Resolution for amendment of Articles of Association of the Company through Postal Ballot. The Company has now informed the Exchange that the Members of the Company through Postal Ballot have approved the aforesaid Special Resolution under Section 31 of the Companies Act, 1956 for amendment of Articles of Association by insertion of new Article on Buyback of Shares and Securities as per Section 77A, 77AA and 77B of the Companies Act, 1956. A copy of Notice of Declaration of Results of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
17 Apr · Results
The Company will announce and publish the Audited Financial Results of the Company for the year ended 31st March 2008 on or before 30th June 2008. Consequently, the Company will not be publishing the Un-Audited Financial Results for the quarter ended 31st March 20081 Apr · Meeting
Pursuant to Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, to transact the following Special Business by the Members of Aurobindo Pharma Limited by passing the following Resolution through Postal Ballot. (1) Special Resolution under Section 31 of the Companies Act, 1956 for alteration of Articles of Association by insertion of new Article on of Association by insertion of new Article on Buyback of Shares and Securities as per Section 77A, 77AA and 77B of the Companies Act, 1956. The Company has appointed Mr. P. Jagannatham partner of M/s Puttaparthi Jagannatham & Co, Company Secretaries as the Scrutinizer (the Scrutinizer) for conducting this postal ballot voting process in a fair and transparent manner. The duly completed form should reach the Scrutinizer before the closing of working hours on or before May 07, 2008. The Scrutinizer will submit his report to the Chairman after completion of the scrutiny and the result of the postal ballot will be announced on or after May 08, 2008. A copy of the notice of postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
31 Mar · Amendments to the Articles of Association
A Resolution was passed by the Board by Circulation on 25.03.2008 to conduct a Postal Ballot to seek approval of the Shareholders of the Company by a Special Resolution in terms of Section 31 of the Companies Act, 1956 to amend the Articles of Association by inserting Buy-back provision, which empowers the Company to purchase/ buy-back its own shares or other securities and enables the Company to utilize the provision of buy-back of Shares/ Securities, if it is required in future. Mr.P. Jagannatham of Puttaparthi Jagannatham & Co., Company Secretaries, Hyderabad, has been appointed as the Scrutinizer for the Postal Ballot process. The Notice of Postal Ballot has been issued to the Shareholders for their approval. The last date for receipt of the Postal Ballot Forms is fixed as 07.05.2008 and the date of Declaration of the Result is fixed as 08.05.200824 Mar · Business
Press release dated March 24, 2008, titled "Aurobindo expands in Europe". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
4 Feb · Updates
Vide its letter dated February 04, 2008, that: "An accident occurred yesterday (3rd February, 2008) in Unit 2 situated at IDA Bollaram, Medak District A.P. This unit has not been in operation and at present a turnkey contract for civil construction/fabrication work is being undertaken by an outside agency for a proposed warehouse. However, this incident will not affect the regular operations of the Company".1 Feb · Business
Press release dated February 01, 2008, titled "Aurobindo Pharma receives tentative approval for Sumatriptan Succinate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
31 Jan · Business
Press release dated January 31, 2008, titled "Aurobindo Pharma receives Rs.70 crores ARV supply contract by NACO". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Business
Press release dated January 30, 2008, titled "Q3 2007-08 Financial Results; Total Income Rs. 549.42 Crs; Net Profit Rs. 55.25 Crs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Management
Mr. K. Ragunathan, has been appointed as an Additional Director of the Company at the Board Meeting held on 30th January 2008. He will function as a Non Executive and Independent Director of the Company.30 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 56956 lacs for quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 4457 lacs for the quarter ending on 31-DEC-2007.30 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 51078 lacs for quarter ending on 31-DEC-2007 against Rs. 52840 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 5525 lacs for the quarter ending on 31-DEC-2007 against Rs. 6012 lacs for the quarter ending on 31-DEC-2006.21 Jan · Business
Press release dated January 21, 2008, titled "Aurobindo Pharma receives approval for Cefdinir Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended December 31, 2007.
Dec 2007
10 Dec · Allotment of shares
The Compensation Committee of the Board on 10th December, 2007 has approved allotment of 25947 Equity Shares of Rs.5/- each at a premium of Rs.357.60 per share under ESOP-2004 Scheme of the Company, Consequent to the allotment the paid up share capital of the Company has increased from 53739321 Equity Shares of Rs.5/- each to 53765268 Equity Shares of Rs.5/- each
Nov 2007
22 Nov · Business
Press release dated November 22, 2007, titled "Aurobindo Pharma receives five product approvals from USFDA including two Paragraph IV products". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Nov · Miscellaneous
A minor fire accident has occurred yesterday night (6th November, 2007) in a part of the one of the production blocks of Unit 5 situated at Pashamylaram, Medak district A.P. This API unit consists of ten production blocks. However, this incident will not affect the regular operations of the said Unit6 Nov · Management
The resignation of Mr. Srinivas Lanka, Non Executive and Independent Director of the Company was taken on record by the Board at its meeting held on 31st October, 2007.1 Nov · Grant of Options
Compensation Committee of the Board at their meeting held on October 31, 2007 considered and approved grant of 18000 options under ESOP-2006 Scheme at a price of Rs.572.50 per option.
Oct 2007
31 Oct · Business
Press release dated October 31, 2007, titled "Aurobindo Pharma declares Q2 2007-08 results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 116072 lacs for half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 12379 lacs for the half year ending on 30-SEP-2007.31 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 62838 lacs for quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 6206 lacs for the quarter ending on 30-SEP-2007.31 Oct · Results
Standalone Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 109155 lacs for half year ending on 30-SEP-2007 against Rs. 91856 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 15946 lacs for the half year ending on 30-SEP-2007 against Rs. 9085 lacs for the half year ending on 30-SEP-2006.31 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 61160 lacs for quarter ending on 30-SEP-2007 against Rs. 48000 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 10092 lacs for the quarter ending on 30-SEP-2007 against Rs. 5464 lacs for the quarter ending on 30-SEP-2006.18 Oct · Board meeting
Meeting on 31 Oct 2007: “Unaudited Results for Qtr & Half year ended Sep 30, 2007”5 Oct · Business
Press release dated October 05, 2007, titled "Aurobindo Pharma receives UK-MHRA clearance for Unit XI". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
13 Sep · Business
Press release dated September 13, 2007, titled "Aurobindo Pharma receives UK-MHRA clearance for Unit I". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Sep · Business
Press release dated September 07, 2007, titled "Aurobindo Pharma receives UK-MHRA clearance for Unit VIII". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Sep · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the quarter ended June 30, 2007. The details of Limited review report and the comments of the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Sep · Business
Press release dated September 06, 2007, titled "Aurobindo Pharma receives EIR for Sterile Drug Formulation Facility from US FDA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
9 Aug · Management
We deeply regret to advise you of the demise of Dr. K. A. Balasubramanian one of the Independent Directors of the Company on 3rd August 2007. Consequently the present strength of the Board has become nine with four Wholetime Directors and five Non-Executive & Independent Directors
Jul 2007
31 Jul · Business
Press release dated July 31, 2007, with respect to Unaudited Financial Results for the quarter ended June 30, 2007. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jul · Meeting
Board of Directors of the Company at their Meeting held on July 31, 2007 have approved the following : 1) The Annual General Meeting of the Company will be held on September 27, 2007. 2) The Register of Members and Share Transfer Books of the Company will be closed from September 18, 2007 to September 27, 2007 (both days inclusive) for the purpose of Annual General Meeting and for payment of Dividend for the year 2006-07.31 Jul · Disclosure
The Compensation Committee of the Board at their meeting held on 31.07.2007 considered and approved the following : 1) Under ESOP -2004 Scheme, 16638 Equity Shares of Rs. 5/- each at a premium of Rs.357.60 per share were allotted. 2) Under ESOP-2006 Scheme 5000 options were granted at a price of Rs. 661.75 per option.31 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 53234 lacs for quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 6173 lacs for the quarter ending on 30-JUN-2007.31 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 47995 lacs for quarter ending on 30-JUN-2007 against Rs. 43856 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5854 lacs for the quarter ending on 30-JUN-2007 against Rs. 3621 lacs for the quarter ending on 30-JUN-2006.21 Jul · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the first quarter ended June 30, 2007.19 Jul · Business
Press release dated July 19, 2007, titled "Aurobindo receives approval from USFDA for Amlodipine Besylate Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Jul · Conversion of FCCBs
Issue of USD 60 Millions Convertible Bonds due 2010. In terms of the issue, the Bonds are convertible at any time on or after September 20, 2005 up to August 01, 2010 by the holders of the Bonds into Equity Shares of Rs.5/- each of the Company at an initial conversion price of Rs.522.036 per share with a fixed rate of exchange on conversion of Rs.43.3925 per US $ 1. Accordingly, pursuant to the application received for conversion from some of the Bondholders, the Committee of the Board of Directors of the Company at its meeting held on July 11, 2007 has considered the request and allotted 3,74,046 Equity Shares of Rs.5/- each for cash at a premium of Rs.517.036 by conversion of Bonds worth USD 4,500,000 in terms of the offer document to the FCCB holders.4 Jul · Change in Board of Directors
Pursuant to the terms and conditions of the shares subscription and shareholder agreement entered into on 1st February 2004, between the Promoters, the Company and the Merlion India Fund (I) Ltd., for issue of 23,70,000 equity shares on preferential basis, Merlion has appointed Mr.Karamjit Singh Butalia as Director on the Board of the Company w.e.f. 18.02.2004. Consequent to sale of 13,34,630 equity shares held by them the aforesaid agreement stands terminated. Accordingly, Mr.Karamjit Singh Butalia has resigned as Director from the Board of the Company w.e.f. 11.06.2007. The Board at its meeting held on 30.06.2007 has taken note of the resignation of Mr. Karamjit Singh Butalia as Director of the Company3 Jul · Business
Press release dated July 03, 2007, titled "Aurobindo received 46th ANDA approval from USFDA for Terbinafine HCL Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.